Search | Clinical Trials Finder

Conditions: Labor Pain
Interventions: No Basal Infusion, Basal infusion, PCEA solution (bupivacaine and fentanyl); Other · Drug
Lead sponsor: Neil Roy Connelly, MD; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
Interventions: Insulin human, Octreotide Acetate, Glucagon, Human Growth Hormone, Dexamethasone Oral, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer, Normal saline, Human albumin; Drug · Other · Dietary Supplement + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes Mellitus
Interventions: AID System, Insulin Lispro; Device · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Insulin Resistance, Prediabetic State, Hyperinsulinemia, Non-Alcoholic Fatty Liver Disease, Obesity
Interventions: Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, [6,6-2H2] D-glucose, 20% D-glucose (aq), BOOST Plus, CORE Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer; Drug · Other · Dietary Supplement + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes
Interventions: Terbutaline, 20% basal insulin reduction, Control; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
Interventions: PDR001, ACZ885, CJM112, TMT212, EGF816; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Diabetes Mellitus, Type 1
Interventions: AT247, NovoLog, Fiasp; Drug
Lead sponsor: Arecor Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Total Knee Replacement, Primary Knee Arthroplasty
Interventions: Fentanyl, Ropivacaine; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Pectus Excavatum
Interventions: Hydromorphone, Morphine; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 8 Years to 18 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Decision Support System, Usual Care; Device · Other
Lead sponsor: Daniel Chernavvsky, MD; Other
Eligibility: 21 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type 1 Diabetes Mellitus, Maturity-Onset Diabetes of the Young, Type 2, MODY2, Insulin Resistance
Interventions: Hyperinsulinemic, euglycemic clamp, 20% dextrose; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 13 Years to 51 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
Interventions: pump, insulin aspart; Device · Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 6
States / cities: Chula Vista, California • Miami, Florida • Witchita, Kansas + 3 more

Conditions: Labor and Delivery
Interventions: Epidural needle, Catheter Administration, Standard of Care Epidural Administration; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 89 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Basal Cell Carcinoma of the Skin, Pain, Recurrent Skin Cancer
Interventions: methyl-5-aminolevulinate hydrochloride cream, photodynamic therapy, laser therapy; Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetes Mellitus
Interventions: Regular Human Insulin, Lispro, VIAject, VIAject 50%, VIAject/Insulin Glargine, Insulin Glargine/VIAject; Drug
Lead sponsor: Biodel; Industry
Eligibility: 19 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Phantom Limb Pain
Interventions: Perineural infusion [continuous peripheral nerve block(s)]; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 4
States / cities: Palo Alto, California • San Diego, California • Bethesda, Maryland + 1 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Faster Insulin Aspart (Fiasp®); Drug
Lead sponsor: Mountain Diabetes and Endocrine Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Asheville, North Carolina

Conditions: Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm, Neoplasms by Site, Papillomavirus Infection, Epstein-Barr Virus Infections, Carcinoma, Neoplasms, Vulvar Neoplasms, Vulvar Diseases, Abdominal Neoplasm, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions: STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere); Drug · Combination Product
Lead sponsor: Marengo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Sacramento, California • Celebration, Florida • Miami, Florida + 10 more

Conditions: Pain, Breastfeeding
Interventions: Group 1, Group 2, Group 3; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: IDDM
Interventions: Continuous Pramlintide infusion; Drug
Lead sponsor: University Diabetes & Endocrine Consultants; Other
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: Insulin Secretion
Interventions: Glucagon; Drug
Lead sponsor: David D'Alessio, M.D.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pain
Interventions: Preservative free morphine, Fentanyl; Drug
Lead sponsor: Goodman, Evan, M.D.; Individual
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, Amifostine, Carboplatin, Etoposide, Ifosfamide, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: Pramlintide; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 13 Years to 22 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Parturient Controlled Epidural Analgesia (PCEA) With or Without a Basal Infusion for Early Labor

Dexamethasone/Pancreatic Clamp P&F

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus

Pancreatic Clamp in NAFLD

Use of Terbutaline or a Reduction in Basal Insulin in the Prevention of Nocturnal Hypoglycemia

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study

Postoperative Knee Strength Following Total Knee Replacement: A Double-Blinded Randomized Comparison Study

A Comparison Trial Between PCA and Epidural Analgesia for Pectus Excavatum Repair

Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM

Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)

A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump

Epidural Loading: High Volume, Low Concentration

Photodynamic Therapy Using Methyl-5-Aminolevulinate Hydrochloride Cream in Determining Pain Threshold in Patients With Skin Cancer

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study

The Efficacy and Safety of Faster Insulin Aspart (Fiasp®) Compared to Conventional Insulin Aspart (NovoLog®) as Correction Bolus

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

The Effect of Neuraxial Analgesia on Maternal Breastfeeding

A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes

Glucagon Regulation of Glucose Metabolism

Epidural Morphine Versus Epidural Fentanyl Infusion Following Cesarean Section

High-dose ICE With Amifostine

Continuous Subcutaneous Infusion of Pramlintide and Insulin